In our research, we focus on the immunotherapy of cervical cancer and liver cirrhosis or -cancer induced by chronic Hepatitis C virus (HCV) infection. The central aim of these strategies is to induce a strong cellular immune response against the tumor involved.
  • For cervical cancer, the tumor antigens aimed for are the E6 and E7 proteins of Human Papillomavirus (HPV), the virus involved in the development of this type of cancer.
  • For liver cancer and cirrhosis, we aim at the induction of an HCV-specific immune response.

Several approaches are being pursued including genetic immunization with recombinant viral vectors based on Semliki Forest virus, immune checkpoint inhibitors and approaches to re-modulate the immunosuppressive tumor environment. We furthermore focus on methods to identify HLA-bound antigenic peptides to generate personalized cancer vaccines.